M. Leehey

发表

Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X

R. Wilson, P. Hagerman, F. Tassone, 2001, Neurology.

Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction.

W. Brown, J. Brunberg, P. Hagerman, 2002, AJNR. American journal of neuroradiology.

Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS).

J Grigsby, B. Trapp, J. Brunberg, 2006, Brain : a journal of neurology.

CGG repeat length correlates with age of onset of motor signs of the fragile X‐associated tremor/ataxia syndrome (FXTAS)

Lexin Li, P. Hagerman, A. Brusco, 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Fragile X-Associated Tremor/Ataxia Syndrome

M. Leehey, 2009, Journal of Investigative Medicine.

Fragile X–associated tremor ataxia syndrome in FMR1 gray zone allele carriers

O. Klepitskaya, D. Hall, F. Tassone, 2012, Movement disorders : official journal of the Movement Disorder Society.

Simultaneous Quantification of 17 Cannabinoids bY LC-MS-MS in Human Plasma.

J. Klawitter, J. Klawitter, U. Christians, 2021, Journal of analytical toxicology.

Clinical Neurological Phenotype of FXTAS

C. Goetz, R. Hagerman, E. Berry-Kravis, 2010 .

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

Tanya Simuni, Jordan J Elm, Debra Babcock, 2015, JAMA.

Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1.

Z. Mari, J. Morgan, Adriana Pérez, 2016, JAMA neurology.

Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America

C. Christine, M. Aminoff, J. Goudreau, 2016, Journal of the Neurological Sciences.

Parkinson's disease severity and use of dopaminergic medications.

C. Christine, M. Aminoff, R. Zweig, 2015, Parkinsonism & related disorders.

Levodopa modulates small‐world architecture of functional brain networks in Parkinson's disease

Korey P. Wylie, E. Kronberg, J. Smucny, 2016, Movement disorders : official journal of the Movement Disorder Society.

Tremor: Diagnosis and Treatment

M. Leehey, 2001 .

Do patients with Parkinson’s disease benefit from embryonic dopamine cell transplantation?

L. Thompson, C. Freed, M. Leehey, 2003, Journal of Neurology.

Prevalence of FMR1 Repeat Expansions in Movement Disorders

P. Hagerman, D. Hall, R. Hagerman, 2006, Neuroepidemiology.

Fragile X-associated tremor/ataxia syndrome.

P. Hagerman, M. Leehey, 2012, Handbook of clinical neurology.

Symptomatic treatment in the fragile X–associated tremor/ataxia syndrome

P. Hagerman, D. Hall, R. Hagerman, 2006, Movement disorders : official journal of the Movement Disorder Society.

Treatment and Management of FXTAS

D. Hall, R. Hagerman, E. Berry-Kravis, 2010 .

Higher Risk, Higher Reward? Self‐Reported Effects of Real‐World Cannabis Use in Parkinson's Disease

Y. Liu, S. Sillau, M. Leehey, 2022, Movement disorders clinical practice.

Acute akathisia following initiation of opicapone: A case report

M. Leehey, J. Bainbridge, Alexander J. Baumgartner, 2022, Clinical parkinsonism & related disorders.

PRNP H187R mutation associated with neuropsychiatric disorders in childhood and dementia

G. Schellenberg, T. Montine, C. Filley, 2005, Neurology.

Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia.

F. Farzin, J. Bourgeois, F. Tassone, 2006, The Journal of clinical psychiatry.

Tremor/Ataxia syndrome in fragile X carrier males

W. Landau, P. Hagerman, F. Tassone, 2002 .

Fragile X-associated tremor ataxia syndrome rating scale: Revision and content validity using a mixed method approach

G. Stebbins, C. Goetz, D. Hall, 2022, Frontiers in Neurology.

Neuropathy as a presenting feature in fragile X‐associated tremor/ataxia syndrome

J. Brunberg, Lin Zhang, P. Hagerman, 2007, American journal of medical genetics. Part A.

Spastic paraparesis, cerebellar ataxia, and intention tremor: a severe variant of FXTAS?

J. Brunberg, P. Hagerman, S. Jacquemont, 2005, Journal of Medical Genetics.

Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study.

L. Seeberger, J. Klawitter, O. Klepitskaya, 2020, Cannabis and cannabinoid research.

Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS)

P. Hagerman, D. Hall, S. Jacquemont, 2005, Neurology.

Akinetic mutism following unilateral anterior cerebral artery occlusion.

D. Arciniegas, M. Leehey, D. Huddle, 2003, The Journal of neuropsychiatry and clinical neurosciences.

Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores

C. Christine, J. Schneider, C. Singer, 2017, Neurology.

Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.

C. Christine, M. Aminoff, R. Zweig, 2017, Journal of Parkinson's disease.

Novel clinical features of glycine receptor antibody syndrome

L. Seeberger, Amanda L. Piquet, J. Bennett, 2019, Neurology: Neuroimmunology & Neuroinflammation.

A Review of the Current Evidence Connecting Seborrheic Dermatitis and Parkinson’s Disease and the Potential Role of Oral Cannabinoids

R. Dellavalle, C. Dunnick, S. Sillau, 2020, Dermatology.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Stephanie D. Wilson, S. Ellias, J. Nutt, 2014, JAMA neurology.

Fragile X‐associated tremor/ataxia syndrome: Clinical features, genetics, and testing guidelines

J. Brunberg, Lin Zhang, P. Hagerman, 2007, Movement disorders : official journal of the Movement Disorder Society.

Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population.

J. Brunberg, Lin Zhang, P. Hagerman, 2004, JAMA.

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

A. Rezai, A. Feigin, S. Tatter, 2011, The Lancet Neurology.

Cannabinoids in Neurologic Conditions

J. Szaflarski, A. Villavicencio, S. Burneikiene, 2020 .

Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.

D. Mozaffarian, Z. Mari, H. Shill, 2021, JAMA.

Emerging topics in FXTAS

G. Stebbins, J. Trollor, S. Fahn, 2014, Journal of Neurodevelopmental Disorders.

Aging in fragile X syndrome

D. Hessl, F. Tassone, R. Hagerman, 2010, Journal of Neurodevelopmental Disorders.

Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS)

D. Loesch, P. Hagerman, S. Jacquemont, 2006, Journal of the Neurological Sciences.

Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers.

M. D. Del Bigio, P. Hagerman, S. Jacquemont, 2002, Brain : a journal of neurology.

FMR1 CGG repeat length predicts motor dysfunction in premutation carriers

C. Goetz, P. Hagerman, D. Hall, 2008, Neurology.

Molecular and imaging correlates of the fragile X–associated tremor/ataxia syndrome

Katherine E. Masyn, S. Rivera, D. Loesch, 2006, Neurology.

Size bias of fragile X premutation alleles in late-onset movement disorders

L. Beckett, P. Hagerman, S. Jacquemont, 2006, Journal of Medical Genetics.

Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation

D. Loesch, P. Hagerman, D. Hessl, 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation.

L Zhang, J Grigsby, B. Leavitt, 2004, American journal of human genetics.

Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates.

W. Brown, J. Brunberg, Lin Zhang, 2003, American journal of human genetics.

Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1

P. Hagerman, S. Jacquemont, R. Hagerman, 2007, The Lancet Neurology.

The primary cognitive deficit among males with fragile X-associated tremor/ataxia syndrome (FXTAS) is a dysexecutive syndrome

P. Hagerman, D. Hessl, F. Tassone, 2008, Journal of clinical and experimental neuropsychology.

Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome.

P. Hagerman, D. Hessl, D. Hall, 2008, Neuropsychology.

Progression of tremor and ataxia in male carriers of the FMR1 premutation

Lin Zhang, P. Hagerman, D. Hessl, 2007, Movement disorders : official journal of the Movement Disorder Society.

Aging in individuals with the FMR1 mutation.

Lin Zhang, P. Hagerman, F. Farzin, 2004, American journal of mental retardation : AJMR.

The International Fragile X Premutation Registry: building a resource for research and clinical trial readiness

Peter K. Todd, D. Hessl, D. Hall, 2022, Journal of Medical Genetics.

Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease.

E. Eskandar, A. Flaherty, J. Henderson, 2017, JCI insight.

Cognitive impairment in a 65-year-old male with the fragile X-associated tremor-ataxia syndrome (FXTAS).

J. Brunberg, P. Hagerman, S. Jacquemont, 2006, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

R. Elble, C. Christine, W. Weiner, 2006, Neurology.

Bovine Myoclonus: Model of Human Hyperekplexia (Startle Disease)

W. Landau, P. Hagerman, F. Tassone, 2002 .

Conversion disorder in women with the FMR1 premutation

J. Olichney, A. Schneider, A. Seritan, 2009, American journal of medical genetics. Part A.

Clinical Phenotype of Adult Fragile X Gray Zone Allele Carriers: a Case Series

R. Shah, C. Filley, O. Klepitskaya, 2016, The Cerebellum.

Parkinsonism in FMR1 premutation carriers may be indistinguishable from Parkinson disease.

D. Hall, R. Hagerman, M. Leehey, 2009, Parkinsonism & related disorders.

Open-label pilot clinical trial of citicoline for fragile X-associated tremor/ataxia syndrome (FXTAS)

D. Hall, B. Ouyang, E. Berry-Kravis, 2020, PloS one.

Chromosome 17 and hereditary dementia

S. M. Sumi, G. Schellenberg, E. Wijsman, 1997, Neurology.

FMR1 gray‐zone alleles: Association with Parkinson's disease in women?

P. Hagerman, D. Hall, B. Ouyang, 2011, Movement disorders : official journal of the Movement Disorder Society.

Neuropathic features in fragile X premutation carriers

Lexin Li, C. Goetz, D. Nguyen, 2007, American journal of medical genetics. Part A.

Tremor and ataxia in fragile X premutation carriers: Blinded videotape study

J. Wuu, C. Goetz, P. Hagerman, 2003, Annals of neurology.

Bell's Palsy in an Older Patient with Uncontrolled Hypertension Due to Medication Nonadherence

S. Ellis, B. Carter, M. Leehey, 1999, The Annals of pharmacotherapy.

Pioglitazone in early Parkinson ' s disease : a phase 2 , multicentre , double-blind , randomised trial NINDS Exploratory Trials in Parkinson Disease ( NET-PD ) FS-ZONE Investigators

R. Pahwa, J. Carter, R. Zweig, 2017 .

Platelet mitochondrial respiratory chain function in Parkinson's disease

M. Leehey, S. Boyson, B. Hoffer, 1997, Movement disorders : official journal of the Movement Disorder Society.

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

J. Jankovic, J. Taylor, C. Adler, 2007, Neurology.

Memantine for fragile X-associated tremor/ataxia syndrome: a randomized, double-blind, placebo-controlled trial.

D. Nguyen, Lin Zhang, P. Hagerman, 2014, The Journal of clinical psychiatry.

Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems

Lin Zhang, P. Hagerman, C. Bodine, 2008, Clinical interventions in aging.

Impairment of executive cognitive functioning in males with fragile X‐associated tremor/ataxia syndrome

D. Loesch, P. Hagerman, D. Hessl, 2007, Movement disorders : official journal of the Movement Disorder Society.

MS vs. HD: Can white matter and subcortical gray matter pathology be distinguished neuropsychologically?

L. Seeberger, C. Filley, M. Leehey, 2007, Journal of clinical and experimental neuropsychology.

Clinical Phenotype of Adult Fragile X Gray Zone Allele Carriers: a Case Series

R. Shah, C. Filley, O. Klepitskaya, 2016, The Cerebellum.

Eye Movements in Fragile X-Associated Tremor/Ataxia Syndrome

V. Pelak, D. Hall, R. Hagerman, 2020, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

Functional status of men with the fragile X premutation, with and without the tremor/ataxia syndrome (FXTAS)

P. Hagerman, J. Grigsby, R. Hagerman, 2009, International journal of geriatric psychiatry.

Neurological and endocrine phenotypes of fragile X carrier women

D. Hall, B. Ouyang, M. Losh, 2016, Clinical genetics.

The fragile X premutation presenting as essential tremor.

A. Lang, A. Lozano, J. Brunberg, 2003, Archives of neurology.

Primary dystonia misinterpreted as Parkinson disease: Video case presentation and practical clues.

O. Klepitskaya, M. Leehey, A. Neuwelt, 2013, Neurology. Clinical practice.

Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study

Michele T. M. Hu, Yen F. Tai, Z. Mari, 2023, Movement disorders clinical practice.

Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of ‘off’ episodes in patients with Parkinson's disease

R. Pahwa, G. Kricorian, M. Leehey, 2007, Current medical research and opinion.

Age‐ and CGG repeat‐related slowing of manual movement in fragile X carriers: A prodrome of fragile X‐associated tremor ataxia syndrome?

S. Rivera, E. Ferrer, D. Hessl, 2018, Movement disorders : official journal of the Movement Disorder Society.

Clinimetric Properties of the Fragile X‐associated Tremor Ataxia Syndrome Rating Scale

G. Stebbins, C. Goetz, Lin Zhang, 2019, Movement disorders clinical practice.

Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.

Y. Liu, J. Klawitter, S. Sillau, 2023, Movement disorders : official journal of the Movement Disorder Society.

Cognitive Impairment in a 65-year-old Male With the Fragile X-associated Tremor-Ataxia Syndrome (FXTAS)

J. Brunberg, P. Hagerman, S. Jacquemont, 2006 .

Fibromyalgia in fragile X mental retardation 1 gene premutation carriers.

F. Tassone, R. Hagerman, M. Leehey, 2011, Rheumatology.

Long-term follow-up of a randomized AAV 2-GAD gene therapy trial for Parkinson ’ s disease

E. Eskandar, A. Flaherty, J. Henderson, 2017 .

Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression

Alyssa, E. Tolosa, D. Galasko, 2023, medRxiv.

Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families.

J. Jankovic, K. Marder, W. Weiner, 2003, Human molecular genetics.

Identifying susceptibility genes for primary ovarian insufficiency on the high-risk genetic background of a fragile X premutation

Cristina E. Trevino, D. Cutler, M. Epstein, 2021, Fertility and sterility.

Parkinsonism in fragile X-associated tremor/ataxia syndrome (FXTAS): revisited.

Lin Zhang, J. Olichney, D. Hall, 2014, Parkinsonism & related disorders.

FMR1 premutation in females diagnosed with multiple sclerosis

J. Brunberg, P. Hagerman, F. Tassone, 2009, Journal of Neurology, Neurosurgery, and Psychiatry.